An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer

Ann Transl Med. 2019 Mar;7(Suppl 1):S53. doi: 10.21037/atm.2019.03.09.
No abstract available

Publication types

  • Editorial
  • Comment